New hope for recurrent endometrial cancer: drug combo shows promise
NCT ID NCT06532539
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests a new combination of the drug cadonilimab plus chemotherapy and radiation for people whose endometrial cancer has come back or spread to a few other spots. About 30 participants will receive the treatment and be monitored for tumor shrinkage, survival, and side effects. The goal is to see if this approach works better than current options and to find markers that predict who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact
Conditions
Explore the condition pages connected to this study.